Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Midazolam for Sedation in Diagnostic Upper GI Endoscopy
NCT05836545Phase 3Completed
- Sponsor
- Samsung Medical Center
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of remimazolam in Procedural sedation (PS) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Total procedure time. Started Apr 2023; status: completed.
02
Drugs
remimazolam
03
Conditions
Procedural sedation (PS)
Beyond the preview
Go deeper on NCT05836545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836545.